Part No: AN721Issued year: 2011File size: 0.3mbFile type: pdf
This application note describes the extraction of Tamoxifen and metabolites from urine using ISOLUTE SLE+ supported liquid extraction plates followed by LC-MS/MS analysis.
ISOLUTE, SLE, SLE+, Tamoxifen, Hormones, Oestrogen
Part No: AN869Issued year: 2016File size: 0.91mbFile type: pdf
This application note describes a solid phase extraction (SPE) protocol, using EVOLUTE EXPRESS ABN solid phase extraction plates, for the extraction of teicoplanin from plasma prior to HPLC-DAD analysis.
Part No: AN740Issued year: 2011File size: 0.38mbFile type: pdf
This application note describes the extraction of testosterone and other steroid hormones from human plasma using ISOLUTE SLE+ supported liquid extraction plates (96-well) with LC-MS/MS analysis. This method describes the use of ISOLUTE SLE+ supported liquid extraction plates (96-well) to extract a range of steroid hormones including testosterone and progesterone from human plasma. This simplified and efficient extraction method has significant analyte recoveries ranging from 90-107% withb LOQs as low as 500 pg/mL.
ISOLUTE, TESTOSTERONE, SLE, SLE+, SUPPORTED LIQUID EXTRACTION, STEROID, HORMONE, PLASMA, ANDROGEN, CLINICAL
Part No: AN809Issued year: 2014File size: 1.3mbFile type: pdf
This application note describes the simultaneous extraction of THC and its major metabolites, including 11-nor-9-carboxy-Δ9-THC glucuronide, from urine using supported liquid extraction (ISOLUTE® SLE+ in both plate and column formats) prior to analysis by LC-MS/MS.
Part No: IST1035Issued year: 2011File size: 0.11mbFile type: pdf
This method was developed for the extraction of the tetrahydrocannabinol carboxylic acid metabolite (THC-COOH) from urine using a mixed non-polar and anion exchange retention mechanism. Typical recoveries of the analyte are > 75%.
THC, THC-COOH, BIOTAGE, ISOLUTE, SPE, DOA, drugs of abuse
Part No: AN867Issued year: 2016File size: 1.28mbFile type: pdf
This application note describes the extraction, using ISOLUTE SLE+ supported liquid extraction columns, of THC, THCA and Carboxy-THC from oral fluid matrix collected using the NeoSal device, prior to GC/MS analysis.
Part No: AN840Issued year: 2015File size: 0.7mbFile type: pdf
This application note describes the extraction of Δ9-THC, 11-hydroxy- Δ9-THC and 11-nor-9-carboxy-THC from whole blood matrix, prior to GC/MS analysis.
An extremely simple sample pre-treatment and extraction method is employed to extract the parent THC and main metabolites from complex whole blood matrix, delivering high, reproducible analyte recoveries.
Part No: AN819Issued year: 2014File size: 1.54mbFile type: pdf
This application note describes the extraction of THC, THCA and Carboxy-THC from oral fluid matrix collected using the Intercept Oral Fluid Drug Test Kit (Orasure Technologies), prior to GC/MS analysis.
Part No: AN822Issued year: 2014File size: 1.57mbFile type: pdf
This application note describes the extraction of THC, THCA and Carboxy-THC from oral fluid matrix collected using the Quantisal™ (Immunalysis) device, prior to GC/MS analysis.
The ISOLUTE SLE+ protocol is optimized for 400 μL and 1 mL sample capacity formats. The simple sample preparation procedure delivers clean extracts and analyte recoveries greater than 75% with RSDs lower than 10% for all analytes.
Part No: AN881Issued year: 2017File size: 1.66mbFile type: pdf
The method described in this application note demonstrates selective extraction of the thyroid hormones T3, rT3 and T4 from serum. 200 μL of serum was extracted using the EVOLUTE® EXPRESS AX 30 mg fixed well plate format. High reproducible recoveries and low phospholipid content were observed, demonstrating limits of quantitation < 50 pg/mL.
Part No: AN884Issued year: 2017File size: 0.62mbFile type: pdf
TSNAs, or tobacco-specific nitrosamines, are carcinogens found in tobacco products, including e-cigarettes and smokeless tobacco. This proof of concept study focusses on NNN (n-nitrosonornicotine), but the supported liquid extraction methodology described is a also suitable for NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol).
Part No: AN716Issued year: 2011File size: 0.14mbFile type: pdf
The following method has been developed for the extraction of the following triazines and triazine metabolites; atrazine, simazine, propazine, cyanazine, sebuthylazine deisopropylatrazine, deethylatrazine, deethylterbutylazine, prometon and hydroxyterbutylazine from water. Recoveries are in the range 80-95% and are reproducible, allowing sharp decision limits. The maximum accepted level of triazines in drinking water is 0.1 μg/L (EU legislation).
AFFINILUTE, MIP, SupelMIP, Molecularly Imprinted Polymer
Part No: AN601Issued year: 2008File size: 0.12mbFile type: pdf
This Application Note describes the development of an automated procedure for high throughput supported-liquid extraction of three tricyclic antidepressant drugs from human plasma, using the ISOLUTE® SLE+ Supported-liquid Extraction Plate. Analyte recovery, along with the speed and efficiency are compared to traditional LLE.
Biotage, Extralute, Ostro, supported liquid extraction, liquid liquid extraction,
Part No: AN712Issued year: 2011File size: 0.09mbFile type: pdf
The following methods have been developed for the selective extraction of tobacco specific nitrosamines (NNN, NNK, NAT, and NAB) from human urine. The method is highly reproducible and offers an average recovery of 80% (95% for NNK and NAT; and 70% for NNN and NAB). Detection limits of 4 pg/mL are readily achieved for urine samples using LC-MS-MS analysis.
MIP, SupelMIP, Molecularly Imprinted Polymer,
Part No: P145Issued year: 2016File size: 0.42mbFile type: pdf
This poster demonstrates a rapid and reliable sample preparation method using Supported Liquid Extraction (ISOLUTE SLE+) to extract a suite of 30 hormone analytes from a hydrolyzed urine matrix. Single injection analysis by LC-MS/MS shows that matrix effects are eliminated by the ISOLUTE SLE+ protocol and that analyte recovery and sensitivity have excellent clinical utility.